| Identification | Back Directory | [Name]
Hexanamide, N-(2-aminophenyl)-6-[[5-oxido-4-(phenylsulfonyl)-1,2,5-oxadiazol-3-yl]oxy]- | [CAS]
2490309-83-4 | [Synonyms]
HDAC-IN-41
Hexanamide, N-(2-aminophenyl)-6-[[5-oxido-4-(phenylsulfonyl)-1,2,5-oxadiazol-3-yl]oxy]- | [Molecular Formula]
C20H22N4O6S | [MOL File]
2490309-83-4.mol | [Molecular Weight]
446.48 |
| Hazard Information | Back Directory | [Uses]
HDAC-IN-41 (Compound 7c) is a selective, orally active class I HDAC inhibitor with IC50 values of 0.62, 1.46 and 0.62 μM against HDAC1, HDAC2 and HDAC3, respectively. HDAC-IN-41 shows NO releasing activity[1]. | [in vivo]
HDAC-IN-41 (Compound 7c) (30 mg/kg/d; p.o., 15 days) inhibits tumor growth in a HCT116 xenograft model in nude mice[1]. | [IC 50]
HDAC1: 0.62 μM (IC50); HDAC3: 0.62 μM (IC50); HDAC2: 1.46 μM (IC50) | [References]
[1] Ding Q, et al. Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity. Bioorg Chem. 2020 Nov;104:104235. DOI:10.1016/j.bioorg.2020.104235 |
|
|